Literature DB >> 9684919

The serotonin syndrome scale: first results on validity.

U Hegerl1, R Bottlender, J Gallinat, H J Kuss, M Ackenheil, H J Möller.   

Abstract

As a modification of the diagnostic criteria of the serotonin syndrome proposed by Sternbach, we developed the Serotonin syndrome scale for the operationalized assessment of both the presence and the severity of the core symptoms of the serotonin syndrome. In a first study on the validity of this scale, the relationships between the serotonin syndrome score (SSS) and both the paroxetine plasma levels (n = 42) and the loudness dependence of the auditory evoked potentials (LDAEP; n = 24) were investigated in depressed patients treated with paroxetine. A strong LDAEP is supposed to indicate low central serotonergic neurotransmission, and vice versa. The SSS was positively related to paroxetine plasma levels and negatively to the LDAEP. Both results support the validity of the serotonin syndrome scale. Using a SSS > 6 as diagnostic criterion, mild serotonin syndromes were diagnosed in 5 of our 42 patients. The Serotonin syndrome scale may become a useful tool for clinicians and scientists dealing with the serotonin syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9684919     DOI: 10.1007/s004060050024

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  16 in total

1.  The future for non-principal general practitioners: lost doctors--lost to whom?

Authors:  J Shakespeare; J Evans
Journal:  Br J Gen Pract       Date:  1999-11       Impact factor: 5.386

2.  Paroxetine withdrawal in a neonate with historical and laboratory confirmation.

Authors:  Sanjay Jaiswal; Robert C Coombs; Geoffrey K Isbister
Journal:  Eur J Pediatr       Date:  2003-08-07       Impact factor: 3.183

3.  [The serotonin syndrome. Fatal course of intoxication with citalopram and moclobemide].

Authors:  S Cassens; E A Nickel; M Quintel; P Neumann
Journal:  Anaesthesist       Date:  2006-11       Impact factor: 1.041

4.  Relationship between SSRI-induced sexual dysfunction and central serotonergic activity based on the loudness dependence of auditory evoked potentials.

Authors:  Young-Min Park
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

5.  Evidence of associations between brain-derived neurotrophic factor (BDNF) serum levels and gene polymorphisms with tinnitus.

Authors:  Aysun Coskunoglu; Seda Orenay-Boyacioglu; Artuner Deveci; Mustafa Bayam; Ece Onur; Arzu Onan; Fethi S Cam
Journal:  Noise Health       Date:  2017 May-Jun       Impact factor: 0.867

6.  Examining the underpinnings of loudness dependence of auditory evoked potentials with positron emission tomography.

Authors:  Rajapillai L I Pillai; Elizabeth A Bartlett; Mala R Ananth; Chencan Zhu; Jie Yang; Greg Hajcak; Ramin V Parsey; Christine DeLorenzo
Journal:  Neuroimage       Date:  2020-03-10       Impact factor: 6.556

7.  "There is no dose-response relationship in psychopharmacotherapy" vs "pharmacotherapy in psychiatry is based on ligand-receptor interaction": a unifying hypothesis and the need for plasma concentration based clinical trials.

Authors:  Vincent Eggart; Christoph Hiemke; Gerald Zernig
Journal:  Psychopharmacology (Berl)       Date:  2011-05-04       Impact factor: 4.530

Review 8.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

9.  Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans.

Authors:  Barry V O'Neill; Rodney J Croft; Sumie Leung; Valérie Guille; Matthew Galloway; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

10.  The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports.

Authors:  Randolph W Evans
Journal:  MedGenMed       Date:  2007-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.